Literature DB >> 1972720

Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production.

K Utsumi1, Y Takai, T Tada, S Ohzeki, H Fujiwara, T Hamaoka.   

Abstract

IL-6 is a cytokine secreted in normal individuals by monocytes, fibroblasts, and endothelial cells. We have found increased levels of IL-6 in the sera from MH134 hepatoma- and CSA1M fibrosarcoma-bearing mice. Concerning the capacity of these tumor cells themselves to produce IL-6 in vitro, they exhibited the distinct contrast, i.e., the MH134 tumor cells produced high levels of IL-6 whereas the CSA1M generated a marginal level of IL-6. It was, however, demonstrated that appreciably enhanced IL-6 production was observed in spleen cell culture supernatants from both types of tumor-bearing mice when compared to those obtained from normal mice. More importantly, in contrast to the production of IL-6 by non-T cell compartment of normal spleen cells, enhanced IL-6 production of spleen cells from tumor-bearing mice was ascribed to T cell compartment. Analysis of T cell phenotype has revealed that enhanced IL-6 production was mediated predominantly by Lyt-2+ but not by L3T4+ T cell subset. Thus, these results indicate that increased circulating IL-6 is elicited in the tumor-bearing state and that irrespective of the potential of tumor cells themselves to produce IL-6, T cells, especially Lyt-2+ T cells from tumor-bearing mice are responsible for such a high level of IL-6 production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972720

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Protein turnover, synthesis and secretion of albumin in hepatocytes isolated from rats bearing Walker 256 carcinoma.

Authors:  P Villa; P Arioli; A Guaitani
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

Review 2.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 3.  The role of photodynamic therapy for hilar cholangiocarcinoma.

Authors:  Young Koog Cheon
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

4.  Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Chang Hwan Yeom; Sang Mi Kwak; Ho Min Yoon; Dae Gyun Kim; Su-Jin Koh; Jeanno Park; Myung Ah Lee; Yong Joo Lee; Ah-Ram Seo; Hong-Yup Ahn; Eunji Yim
Journal:  Support Care Cancer       Date:  2013-07-05       Impact factor: 3.603

5.  Anticonvulsant-induced suppression of IFN-gamma production by lymphocytes obtained from cervical lymph nodes in glioma-bearing mice.

Authors:  M Yamada; M Ohkawa; K Tamura; E Mabuchi; H Kishima; M Tamura; K Shimizu
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

6.  Interleukin-6 and acute-phase proteins in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; T Brunelli; E Gallina
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

7.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

8.  Current status of photodynamic therapy for bile duct cancer.

Authors:  Tae Yoon Lee; Young Koog Cheon; Chan Sup Shim
Journal:  Clin Endosc       Date:  2013-01-31

9.  Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Authors:  A Eisenthal; Y Skornick; O Merimsky; R Hirsch; V Zakut; I Ron; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

Review 10.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.